Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity

Cancer Letters

Volumn 358, Issue 2, 2015, Pages 161-169

  Schenk, Miriam ^a   Aykut, Berk ^a   Teske, Christian ^b   Giese, Nathalia A ^a   Weitz, Juergen ^b   Welsch, Thilo ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Migration; Pancreatic cancer; RhoA; Salinomycin; Stress fibers

Indexed keywords

ACTIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SALINOMYCIN; PYRAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LIVER METASTASIS; MEMBRANE DAMAGE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERITONEUM METASTASIS; PROTEIN FUNCTION; STRESS FIBER; ANIMAL; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; METASTASIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

MUS;

ACTINS; ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MICE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PYRANS; RHOA GTP-BINDING PROTEIN; STRESS FIBERS; TUMOR BURDEN;

EID: 84921549853     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.037     Document Type: Article

References (37)

1. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
2. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med 2013, 369:1691-1703.
3. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
4. Mitani M., Yamanishi T., Miyazaki Y. Salinomycin: a new monovalent cation ionophore. Biochem. Biophys. Res. Commun 1975, 66:1231-1236.
5. Miyazaki Y., Shibuya M., Sugawara H., Kawaguchi O., Hirsoe C. Salinomycin, a new polyether antibiotic. J. Antibiot. (Tokyo) 1974, 27:814-821.
6. Ketola K., Hilvo M., Hyotylainen T., Vuoristo A., Ruskeepaa A.L., Oresic M., et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br. J. Cancer 2012, 106:99-106.
7. Kim K.Y., Yu S.N., Lee S.Y., Chun S.S., Choi Y.L., Park Y.M., et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem. Biophys. Res. Commun 2011, 413:80-86.
8. Li T., Su L., Zhong N., Hao X., Zhong D., Singhal S., et al. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy 2013, 9:1057-1068.
9. Lu D., Choi M.Y., Yu J., Castro J.E., Kipps T.J., Carson D.A. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13253-13257.
10. Kopp F., Hermawan A., Oak P.S., Herrmann A., Wagner E., Roidl A. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol. Cancer 2014, 13:16.
11. Ridley A.J. Life at the leading edge. Cell 2011, 145:1012-1022.
12. Serba S., Schmidt J., Wentzensen N., Ryschich E., Marten A. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 2008, 57:344-351.
13. Koo K.H., Kim H., Bae Y.K., Kim K., Park B.K., Lee C.H., et al. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis 2013, 4:e693.
14. Pellegrin S., Mellor H. Actin stress fibres. J. Cell Sci 2007, 120:3491-3499.
15. Vignjevic D., Kojima S., Aratyn Y., Danciu O., Svitkina T., Borisy G.G. Role of fascin in filopodial protrusion. J. Cell Biol 2006, 174:863-875.
16. Welsch T., Keleg S., Bergmann F., Bauer S., Hinz U., Schmidt J. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas 2009, 38:968-976.
17. O'Connor K., Chen M. Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases 2013, 4:141-147.
18. Machesky L.M., Hall A. Role of actin polymerization and adhesion to extracellular matrix in Rac- and Rho-induced cytoskeletal reorganization. J. Cell Biol 1997, 138:913-926.
19. Schoenwaelder S.M., Petch L.A., Williamson D., Shen R., Feng G.S., Burridge K. The protein tyrosine phosphatase Shp-2 regulates RhoA activity. Curr. Biol 2000, 10:1523-1526.
20. Katoh K., Kano Y., Ookawara S. Rho-kinase dependent organization of stress fibers and focal adhesions in cultured fibroblasts. Genes Cells 2007, 12:623-638.
21. Burridge K., Doughman R. Front and back by Rho and Rac. Nat. Cell Biol 2006, 8:781-782.
22. Sander E.E., ten Klooster J.P., van Delft S., van der Kammen R.A., Collard J.G. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J. Cell Biol 1999, 147:1009-1022.
23. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
24. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
25. Abel E.V., Simeone D.M. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013, 144:1241-1248.
26. Welsch T., Keleg S., Bergmann F., Degrate L., Bauer S., Schmidt J. Comparative analysis of tumor biology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clin. Exp. Metastasis 2009, 26:701-711.
27. Fuchs D., Heinold A., Opelz G., Daniel V., Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem. Biophys. Res. Commun 2009, 390:743-749.
28. He L., Wang F., Dai W.Q., Wu D., Lin C.L., Wu S.M., et al. Mechanism of action of salinomycin on growth and migration in pancreatic cancer cell lines. Pancreatology 2013, 13:72-78.
29. Zhang G.N., Liang Y., Zhou L.J., Chen S.P., Chen G., Zhang T.P., et al. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett 2011, 313:137-144.
30. Ridley A.J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 2006, 16:522-529.
31. Yamazaki D., Kurisu S., Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005, 96:379-386.
32. Olson M.F., Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis 2009, 26:273-287.
33. Hoon J.L., Wong W.K., Koh C.G. Functions and regulation of circular dorsal ruffles. Mol. Cell. Biol 2012, 32:4246-4257.
34. Naujokat C., Fuchs D., Opelz G. Salinomycin in cancer: a new mission for an old agent. Mol Med Rep 2010, 3:555-559.
35. Naujokat C., Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol 2012, 2012:950658.
36. Nimnual A.S., Taylor L.J., Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. Nat. Cell Biol 2003, 5:236-241.
37. Ohta Y., Hartwig J.H., Stossel T.P. FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling. Nat. Cell Biol 2006, 8:803-814.